Trials / Completed
CompletedNCT02836457
ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,134 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study is to estimate the real-world safety profile of Eliquis in Japanese Venous Thromboembolism patients and to estimate the risk factors likely to affect the incidence of bleeding. Lastly, the secondary objective of this study is to estimate the real-world effectiveness profile of Eliquis in Japanese Venous Thromboembolism patients.
Conditions
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2018-07-31
- Completion
- 2018-07-31
- First posted
- 2016-07-19
- Last updated
- 2022-02-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02836457. Inclusion in this directory is not an endorsement.